PTC Therapeutics (NASDAQ:PTCT) EVP Sells $172,290.24 in Stock

February 21, 2026 by InsiderTrades.com

Key Points

CFO Pierre Gravier sold 2,992 PTC shares on Feb. 18 at an average price of $69.36 for roughly $207,525, reducing his stake by 3.31% to 87,318 shares (he also sold 2,139 shares on Jan. 6 at $76.95).
PTC posted a material Q4 miss with EPS of ($1.67) vs. ($0.21) expected and revenue $164.7M versus $281.5M consensus, and management set FY‑2026 revenue guidance at $700M–$800M versus Street ~ $974M.
Multiple executives sold shares around Feb. 17–18 (a clustered insider sell), while analysts trimmed price targets but largely remain positive—consensus is a "Moderate Buy" with an average target near $80.73.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 2,484 shares of the company's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $172,290.24. Following the completion of the transaction, the executive vice president owned 89,944 shares in the company, valued at approximately $6,238,515.84. The trade was a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lee Scott Golden also recently made the following trade(s):

On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total value of $66,205.70.
On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $49,742.16.
On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $103,113.00.

PTC Therapeutics Trading Up 1.1%

Shares of PTCT opened at $70.66 on Friday. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The stock has a fifty day moving average price of $74.91 and a 200-day moving average price of $67.91. The firm has a market cap of $5.67 billion, a PE ratio of 9.13 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to analysts' expectations of $281.45 million. PTC Therapeutics had a negative return on equity of 373.67% and a net margin of 39.44%.The firm's revenue for the quarter was down 22.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.85) EPS. As a group, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a "buy" rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Analyst Ratings Changes

A number of brokerages have commented on PTCT. Citigroup increased their target price on PTC Therapeutics from $50.00 to $75.00 and gave the company a "neutral" rating in a report on Wednesday, November 5th. Bank of America cut their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a "buy" rating for the company in a report on Friday. Cantor Fitzgerald restated an "overweight" rating on shares of PTC Therapeutics in a report on Friday. Wells Fargo & Company dropped their price target on shares of PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating for the company in a research note on Friday. Finally, The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a "sell" rating in a research note on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, PTC Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $80.73.

View Our Latest Stock Report on PTC Therapeutics

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors have recently made changes to their positions in the stock. UMB Bank n.a. purchased a new stake in PTC Therapeutics during the fourth quarter worth $26,000. Smartleaf Asset Management LLC raised its stake in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. lifted its stake in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 249 shares in the last quarter. Comerica Bank grew its stake in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in shares of PTC Therapeutics in the fourth quarter valued at $41,000.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.